Acceleron Pharma Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/1/2021)
| Balance Sheet | Total Assets | 932,337,000.00 | ROE | – |
| Balance Sheet | Total Equity | 855,107,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -4,203,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -134,530,000.00 | – | – |
| Cashflow | Operating Cash Flow | -130,327,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -2.92 | Div. Yield | – |
| Income | Net Income | -166,030,000.00 | P/E | – |
| Income | Shares Outstanding | 60,383,900.00 | P/B | – |
| Income | Total Revenue | 92,523,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.acceleronpharma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more